Claims for Patent: 8,236,558

Summary for Patent: 8,236,558

Title:	Bovine immunodeficiency virus (BIV) based vectors
Abstract:	BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.
Inventor(s):	Luo; Tianci (Clarksville, MD), Berkowitz; Robert (San Francisco, CA), Kaleko; Michael (Potomac, MD)
Assignee:	Novartis AG (Basel, CH)
Application Number:	12/871,902
Patent Claims:	1. A bovine immunodeficiency virus (BIV) packaging construct comprising a BIV DNA sequence fragment comprising at least a gag or a pol gene of BIV, and a promoter operably linked to said BIV DNA fragment. 2. The BIV construct of claim 1 further comprising an internal ribosome binding site. 3. The BIV construct of claim 1 further comprising a heterologous intron. 4. A BIV packaging cell line comprising an established cell line transformed by the BIV construct of claim 1. 5. A packaging construct comprising a promoter operatively linked to a BIV gag/pol coding sequence and a polyadenylation signal at the 3' end of said gag/pol coding sequence. 6. The packaging construct of claim 5, further comprising an intron upstream of said gag/pol coding sequence. 7. The packaging construct of claim 5, further comprising an RNA transport element. 8. The packaging construct of claim 7, wherein said RNA transport element comprises a lentiviral rev response element (RRE). 9. The packaging construct of claim 8, wherein said lentiviral RRE comprises a BIV RRE. 10. The packaging construct of claim 7, wherein said RNA transport element comprises a constitutive transport element (CTE). 11. The packaging construct of claim 10, wherein said CTE is a Mason-Pfizer monkey virus CTE. 12. The packaging construct of claim 8, further comprising a Rev coding sequence. 13. A method of making a packaging cell comprising the steps of (1) transfecting a cell with a BIV gag/pol coding sequence and (2) transfecting the cell with a viral envelope coding sequence. 14. The method of claim 13, wherein said cell is a mammalian cell. 15. The method of claim 14, wherein said mammalian cell is a human cell. 16. A method of making a producer cell comprising transfecting the packaging cell of claim 13 with a transfer vector comprising a transgene.

Details for Patent 8,236,558

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-12-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-12-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-12-14